[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fAf0EGBpNTimAuxz6N68IB773LHu3T-rcv2HPC3Ev3WE":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":69,"rows":76},"Tomsk National Research Medical Center of the Russian Academy of Sciences",[4],70,false,21,1,107160,11,39,[14,17,20,23,25,27,29,31],{"name":15,"count":16},"Coronary Artery Disease",6,{"name":18,"count":19},"Breast Cancer Female",5,{"name":21,"count":22},"Myocardial Infarction",4,{"name":24,"count":22},"Primary Breast Cancer",{"name":26,"count":22},"Breast Cancer",{"name":28,"count":22},"Ischemic Cardiomyopathy",{"name":30,"count":22},"Heart Failure",{"name":32,"count":33},"Prostate Cancer",3,[35,40,45,50,55,59,64],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT06170372","High-dose Inhalations of Nitric Oxide in the Treatment of Pneumonia","2026-01-15","200 ppm Nitric Oxide",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT07292571","Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107","2026-03-30","Injection of [99mTc]Tc-ZHER2:4107, SPECT\u002FCT",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05793996","The Prevalence of Iron Deficiency and the Effectiveness of Ferinject® in Patients With HFpEF (ID-HFpEF)","2026-12","Ferinject",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT07457541","Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI","2026-12-31","[99mTc]Tc-HYNIC-FAPI",{"nctId":56,"briefTitle":57,"date":53,"intervention":58},"NCT07275463","[99mTc]Tc-DB8 Accumulation in Primary Tumor in Breast Cancer With Positive and Negative Estrogen Receptor Expression","[99mTc]Tc-DB8",{"nctId":60,"briefTitle":61,"date":62,"intervention":63},"NCT07487714","Comparative Efficacy of 100-, 200-, & 400-mg Amiodarone in Patients With Paroxysmal AF Depending on Plasma Concentration","2027-05","Pharmacotherapy with amiodarone 200 mg per day",{"nctId":65,"briefTitle":66,"date":67,"intervention":68},"NCT07475390","99mTc-1-thio-D-glucose SPECT\u002FCT Versus 18F-Fluoroethyl-l-tyrosine PET\u002FCT in Brain Tumor Imaging","2027-12-31","99mTc-1-thio-D-glucose",[70,71,72,73,74,75],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[77,101,128,146,164,184,204,230,302,324,342,360,385,413,431,457,483,501,526,567,591,615,638,664,687,719,737,767,785,803,821,839,862,885,912,930,954],{"intervention":49,"totalTrials":9,"cells":78},{"EARLY_PHASE1":79,"PHASE1":82,"PHASE2":84,"PHASE3":86,"PHASE4":88,"NA":99},{"trials":80,"activeCount":81},[],0,{"trials":83,"activeCount":81},[],{"trials":85,"activeCount":81},[],{"trials":87,"activeCount":81},[],{"trials":89,"activeCount":9,"soonestReadout":48},[90],{"nctId":46,"briefTitle":47,"status":91,"phases":92,"primaryCompletion":48,"completion":48,"start":93,"enrollment":94,"conditions":95,"interventions":98},"RECRUITING",[74],"2023-04-28",100,[96,97],"Chronic Heart Failure","Iron Deficiency, Latent",[49],{"trials":100,"activeCount":81},[],{"intervention":63,"totalTrials":9,"cells":102},{"EARLY_PHASE1":103,"PHASE1":105,"PHASE2":107,"PHASE3":109,"PHASE4":111,"NA":126},{"trials":104,"activeCount":81},[],{"trials":106,"activeCount":81},[],{"trials":108,"activeCount":81},[],{"trials":110,"activeCount":81},[],{"trials":112,"activeCount":9,"soonestReadout":62},[113],{"nctId":60,"briefTitle":61,"status":114,"phases":115,"primaryCompletion":62,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":123},"ENROLLING_BY_INVITATION",[74],"2027-08","2026-01-12",80,[120,121,122],"Paroxysmal AF","Treatment Decisions","Therapeutic Drug Monitoring (TDM)",[63,124,125],"Treatment with Amiodarone at a dose 100 mg per day","Treatment with Amiodarone at a dose 400 mg per day",{"trials":127,"activeCount":81},[],{"intervention":124,"totalTrials":9,"cells":129},{"EARLY_PHASE1":130,"PHASE1":132,"PHASE2":134,"PHASE3":136,"PHASE4":138,"NA":144},{"trials":131,"activeCount":81},[],{"trials":133,"activeCount":81},[],{"trials":135,"activeCount":81},[],{"trials":137,"activeCount":81},[],{"trials":139,"activeCount":9,"soonestReadout":62},[140],{"nctId":60,"briefTitle":61,"status":114,"phases":141,"primaryCompletion":62,"completion":116,"start":117,"enrollment":118,"conditions":142,"interventions":143},[74],[120,121,122],[63,124,125],{"trials":145,"activeCount":81},[],{"intervention":125,"totalTrials":9,"cells":147},{"EARLY_PHASE1":148,"PHASE1":150,"PHASE2":152,"PHASE3":154,"PHASE4":156,"NA":162},{"trials":149,"activeCount":81},[],{"trials":151,"activeCount":81},[],{"trials":153,"activeCount":81},[],{"trials":155,"activeCount":81},[],{"trials":157,"activeCount":9,"soonestReadout":62},[158],{"nctId":60,"briefTitle":61,"status":114,"phases":159,"primaryCompletion":62,"completion":116,"start":117,"enrollment":118,"conditions":160,"interventions":161},[74],[120,121,122],[63,124,125],{"trials":163,"activeCount":81},[],{"intervention":44,"totalTrials":9,"cells":165},{"EARLY_PHASE1":166,"PHASE1":168,"PHASE2":170,"PHASE3":178,"PHASE4":180,"NA":182},{"trials":167,"activeCount":81},[],{"trials":169,"activeCount":81},[],{"trials":171,"activeCount":9,"soonestReadout":43},[172],{"nctId":41,"briefTitle":42,"status":114,"phases":173,"primaryCompletion":43,"completion":43,"start":174,"enrollment":175,"conditions":176,"interventions":177},[72],"2025-10-20",50,[24],[44],{"trials":179,"activeCount":81},[],{"trials":181,"activeCount":81},[],{"trials":183,"activeCount":81},[],{"intervention":58,"totalTrials":9,"cells":185},{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":198,"PHASE4":200,"NA":202},{"trials":187,"activeCount":81},[],{"trials":189,"activeCount":81},[],{"trials":191,"activeCount":9,"soonestReadout":53},[192],{"nctId":56,"briefTitle":57,"status":114,"phases":193,"primaryCompletion":53,"completion":53,"start":194,"enrollment":195,"conditions":196,"interventions":197},[72],"2025-10-01",40,[24],[58],{"trials":199,"activeCount":81},[],{"trials":201,"activeCount":81},[],{"trials":203,"activeCount":81},[],{"intervention":54,"totalTrials":9,"cells":205},{"EARLY_PHASE1":206,"PHASE1":208,"PHASE2":222,"PHASE3":224,"PHASE4":226,"NA":228},{"trials":207,"activeCount":81},[],{"trials":209,"activeCount":9,"soonestReadout":53},[210],{"nctId":51,"briefTitle":52,"status":211,"phases":212,"primaryCompletion":53,"completion":213,"start":214,"enrollment":215,"conditions":216,"interventions":221},"ACTIVE_NOT_RECRUITING",[71],"2027-05-31","2026-02-26",15,[217,218,219,220],"Lung Cancer (Locally Advanced or Metastatic)","Pancreas Cancer, Metastatic","Breast Cancer (Locally Advanced or Metastatic)","Colorectal Cancer (Locally Advanced or Metastatic)",[54],{"trials":223,"activeCount":81},[],{"trials":225,"activeCount":81},[],{"trials":227,"activeCount":81},[],{"trials":229,"activeCount":81},[],{"intervention":231,"totalTrials":19,"cells":232},"Sham treatment",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":255,"PHASE4":257,"NA":259},{"trials":234,"activeCount":81},[],{"trials":236,"activeCount":81},[],{"trials":238,"activeCount":81},[239],{"nctId":240,"briefTitle":241,"status":242,"phases":243,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":248,"interventions":253},"NCT05757557","Perioperative Nitric Oxide Prevents Acute Kidney Injury in Cardiac Surgery Patients With Chronic Kidney Disease","COMPLETED",[71,72],"2024-12-31","2025-01-31","2023-02-25",136,[249,250,251,252],"Acute Kidney Disease","Chronic Kidney Disease","Cardiac Surgery","Cardiopulmonary Bypass",[231,254],"80-ppm NO",{"trials":256,"activeCount":81},[],{"trials":258,"activeCount":81},[],{"trials":260,"activeCount":9,"soonestReadout":38},[261,273,285,295],{"nctId":262,"briefTitle":263,"status":242,"phases":264,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":269,"interventions":271},"NCT07018895","Personalized Hypoxic-hyperoxic Preconditioning in Elderly People",[75],"2025-09-01","2025-10-03","2025-07-01",20,[270],"Preconditioning",[231,272],"FiO2 reduced by 20% alternating with 34% FiO2",{"nctId":274,"briefTitle":275,"status":242,"phases":276,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":281,"interventions":283},"NCT06162455","High-dose Inhaled NO Therapy for the Prevention of Nosocomial Pneumonia After Cardiac Surgery With CPB",[75],"2024-01-15","2024-02-06","2023-11-17",74,[282],"Nosocomial Pneumonia",[231,284],"200- ppm NO",{"nctId":286,"briefTitle":287,"status":242,"phases":288,"primaryCompletion":289,"completion":194,"start":290,"enrollment":291,"conditions":292,"interventions":293},"NCT06261827","High-dose Inhaled NO Therapy for the pREvenvention of NP After Cardiac Surgery Under CPB",[75],"2025-05-20","2024-02-20",160,[282],[231,294],"200-ppm NO",{"nctId":36,"briefTitle":37,"status":91,"phases":296,"primaryCompletion":38,"completion":297,"start":277,"enrollment":298,"conditions":299,"interventions":301},[75],"2027-01-15",200,[282,300],"Community-acquired Pneumonia",[39,231],{"intervention":68,"totalTrials":9,"cells":303},{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":314},{"trials":305,"activeCount":81},[],{"trials":307,"activeCount":81},[],{"trials":309,"activeCount":81},[],{"trials":311,"activeCount":81},[],{"trials":313,"activeCount":81},[],{"trials":315,"activeCount":9,"soonestReadout":67},[316],{"nctId":65,"briefTitle":66,"status":211,"phases":317,"primaryCompletion":67,"completion":318,"start":319,"enrollment":195,"conditions":320,"interventions":322},[75],"2028-05-31","2026-02-15",[321],"Glioma (Any Grade) in the Brain",[68,323],"18F-FET",{"intervention":323,"totalTrials":9,"cells":325},{"EARLY_PHASE1":326,"PHASE1":328,"PHASE2":330,"PHASE3":332,"PHASE4":334,"NA":336},{"trials":327,"activeCount":81},[],{"trials":329,"activeCount":81},[],{"trials":331,"activeCount":81},[],{"trials":333,"activeCount":81},[],{"trials":335,"activeCount":81},[],{"trials":337,"activeCount":9,"soonestReadout":67},[338],{"nctId":65,"briefTitle":66,"status":211,"phases":339,"primaryCompletion":67,"completion":318,"start":319,"enrollment":195,"conditions":340,"interventions":341},[75],[321],[68,323],{"intervention":39,"totalTrials":9,"cells":343},{"EARLY_PHASE1":344,"PHASE1":346,"PHASE2":348,"PHASE3":350,"PHASE4":352,"NA":354},{"trials":345,"activeCount":81},[],{"trials":347,"activeCount":81},[],{"trials":349,"activeCount":81},[],{"trials":351,"activeCount":81},[],{"trials":353,"activeCount":81},[],{"trials":355,"activeCount":9,"soonestReadout":38},[356],{"nctId":36,"briefTitle":37,"status":91,"phases":357,"primaryCompletion":38,"completion":297,"start":277,"enrollment":298,"conditions":358,"interventions":359},[75],[282,300],[39,231],{"intervention":361,"totalTrials":9,"cells":362},"Ropren",{"EARLY_PHASE1":363,"PHASE1":365,"PHASE2":367,"PHASE3":369,"PHASE4":381,"NA":383},{"trials":364,"activeCount":81},[],{"trials":366,"activeCount":81},[],{"trials":368,"activeCount":81},[],{"trials":370,"activeCount":81},[371],{"nctId":372,"briefTitle":373,"status":242,"phases":374,"primaryCompletion":375,"completion":376,"start":377,"enrollment":6,"conditions":378,"interventions":380},"NCT03122340","Polyprenols (Ropren) in Acute Coronary Syndrome",[73],"2017-12-31","2018-02-28","2015-11-01",[379],"Acute Coronary Syndrome",[361],{"trials":382,"activeCount":81},[],{"trials":384,"activeCount":81},[],{"intervention":386,"totalTrials":9,"cells":387},"Nitric Oxide-Sessions",{"EARLY_PHASE1":388,"PHASE1":390,"PHASE2":392,"PHASE3":407,"PHASE4":409,"NA":411},{"trials":389,"activeCount":81},[],{"trials":391,"activeCount":81},[],{"trials":393,"activeCount":81},[394],{"nctId":395,"briefTitle":396,"status":242,"phases":397,"primaryCompletion":398,"completion":399,"start":400,"enrollment":268,"conditions":401,"interventions":405},"NCT04476992","Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement",[71,72],"2021-07-17","2021-09-17","2020-07-24",[402,403,404],"Hypoxemia","Pneumonia, Viral","Coronavirus Infection",[386,406],"Nitric Oxide-Continuous and Sessions",{"trials":408,"activeCount":81},[],{"trials":410,"activeCount":81},[],{"trials":412,"activeCount":81},[],{"intervention":406,"totalTrials":9,"cells":414},{"EARLY_PHASE1":415,"PHASE1":417,"PHASE2":419,"PHASE3":425,"PHASE4":427,"NA":429},{"trials":416,"activeCount":81},[],{"trials":418,"activeCount":81},[],{"trials":420,"activeCount":81},[421],{"nctId":395,"briefTitle":396,"status":242,"phases":422,"primaryCompletion":398,"completion":399,"start":400,"enrollment":268,"conditions":423,"interventions":424},[71,72],[402,403,404],[386,406],{"trials":426,"activeCount":81},[],{"trials":428,"activeCount":81},[],{"trials":430,"activeCount":81},[],{"intervention":432,"totalTrials":9,"cells":433},"SPECT or SPECT-CT with 99mTc-1-thio-D-glucose",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":451,"PHASE4":453,"NA":455},{"trials":435,"activeCount":81},[],{"trials":437,"activeCount":81},[],{"trials":439,"activeCount":81},[440],{"nctId":441,"briefTitle":442,"status":242,"phases":443,"primaryCompletion":444,"completion":444,"start":445,"enrollment":446,"conditions":447,"interventions":450},"NCT04288518","Molecular Imaging of Brain Tumors Using Labeled Technetium-99m 1-Thio-D-Glucose.",[71,72],"2021-02-15","2020-02-15",16,[448,449],"Brain","Neoplasms",[432],{"trials":452,"activeCount":81},[],{"trials":454,"activeCount":81},[],{"trials":456,"activeCount":81},[],{"intervention":458,"totalTrials":9,"cells":459},"Nitric Oxide",{"EARLY_PHASE1":460,"PHASE1":462,"PHASE2":464,"PHASE3":477,"PHASE4":479,"NA":481},{"trials":461,"activeCount":81},[],{"trials":463,"activeCount":81},[],{"trials":465,"activeCount":81},[466],{"nctId":467,"briefTitle":468,"status":242,"phases":469,"primaryCompletion":470,"completion":470,"start":471,"enrollment":472,"conditions":473,"interventions":476},"NCT03500783","Nitric Oxide-mediated Cardioprotection During Cardiac Surgery With Cardiopulmonary Bypass",[71,72],"2016-11-30","2015-05-15",60,[15,474,252,458,475],"Coronary Artery Bypass","Reperfusion Injury, Myocardial",[458],{"trials":478,"activeCount":81},[],{"trials":480,"activeCount":81},[],{"trials":482,"activeCount":81},[],{"intervention":254,"totalTrials":9,"cells":484},{"EARLY_PHASE1":485,"PHASE1":487,"PHASE2":489,"PHASE3":495,"PHASE4":497,"NA":499},{"trials":486,"activeCount":81},[],{"trials":488,"activeCount":81},[],{"trials":490,"activeCount":81},[491],{"nctId":240,"briefTitle":241,"status":242,"phases":492,"primaryCompletion":244,"completion":245,"start":246,"enrollment":247,"conditions":493,"interventions":494},[71,72],[249,250,251,252],[231,254],{"trials":496,"activeCount":81},[],{"trials":498,"activeCount":81},[],{"trials":500,"activeCount":81},[],{"intervention":502,"totalTrials":9,"cells":503},"ADAPT6-SPECT",{"EARLY_PHASE1":504,"PHASE1":506,"PHASE2":508,"PHASE3":520,"PHASE4":522,"NA":524},{"trials":505,"activeCount":81},[],{"trials":507,"activeCount":81},[],{"trials":509,"activeCount":81},[510],{"nctId":511,"briefTitle":512,"status":242,"phases":513,"primaryCompletion":514,"completion":514,"start":515,"enrollment":516,"conditions":517,"interventions":519},"NCT05412446","99mTc-ADAPT6 SPECT-based Non-invasive Quantification of HER2-expression in Breast Cancer With Metastatic Lymph Nodes",[72],"2022-12-31","2022-05-01",30,[26,518],"Female",[502],{"trials":521,"activeCount":81},[],{"trials":523,"activeCount":81},[],{"trials":525,"activeCount":81},[],{"intervention":527,"totalTrials":33,"cells":528},"SPECT",{"EARLY_PHASE1":529,"PHASE1":531,"PHASE2":559,"PHASE3":561,"PHASE4":563,"NA":565},{"trials":530,"activeCount":81},[],{"trials":532,"activeCount":81},[533,542,551],{"nctId":534,"briefTitle":535,"status":242,"phases":536,"primaryCompletion":537,"completion":538,"start":539,"enrollment":516,"conditions":540,"interventions":541},"NCT04277338","Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-HE3-G3",[71],"2021-02-10","2021-10-04","2020-02-10",[24],[527],{"nctId":543,"briefTitle":544,"status":242,"phases":545,"primaryCompletion":546,"completion":546,"start":547,"enrollment":548,"conditions":549,"interventions":550},"NCT05923177","Molecular Imaging of HER2 Expression in Breast Cancer Using [123I] I-(HE)3-G3",[71],"2024-09-01","2023-09-01",10,[24],[527],{"nctId":552,"briefTitle":553,"status":242,"phases":554,"primaryCompletion":555,"completion":555,"start":556,"enrollment":516,"conditions":557,"interventions":558},"NCT05203497","Molecular Imaging of HER2 Expression in Breast Cancer Using 99mTc-ZHER2.",[71],"2023-03-01","2021-12-22",[18],[527],{"trials":560,"activeCount":81},[],{"trials":562,"activeCount":81},[],{"trials":564,"activeCount":81},[],{"trials":566,"activeCount":81},[],{"intervention":568,"totalTrials":9,"cells":569},"Diagnostic injection of [123I]I-DARPIN-Ec1",{"EARLY_PHASE1":570,"PHASE1":572,"PHASE2":583,"PHASE3":585,"PHASE4":587,"NA":589},{"trials":571,"activeCount":81},[],{"trials":573,"activeCount":81},[574],{"nctId":575,"briefTitle":576,"status":242,"phases":577,"primaryCompletion":244,"completion":244,"start":578,"enrollment":548,"conditions":579,"interventions":582},"NCT06386653","Molecular Imaging of EpCAM Receptors Using [123I]I-DARPIN-Ec1",[71],"2024-04-14",[580,581],"Lung Cancer","Ovarian Cancer",[568],{"trials":584,"activeCount":81},[],{"trials":586,"activeCount":81},[],{"trials":588,"activeCount":81},[],{"trials":590,"activeCount":81},[],{"intervention":592,"totalTrials":9,"cells":593},"Whole body study and SPECT with [99mTc]Tc-BQ0413",{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":607,"PHASE3":609,"PHASE4":611,"NA":613},{"trials":595,"activeCount":81},[],{"trials":597,"activeCount":81},[598],{"nctId":599,"briefTitle":600,"status":242,"phases":601,"primaryCompletion":602,"completion":603,"start":604,"enrollment":548,"conditions":605,"interventions":606},"NCT06101927","Molecular Imaging of Prostate-Specific Membrane Antigen Using Labeled Technetium-99m BQ0413",[71],"2024-05-31","2024-12-30","2023-10-19",[32],[592],{"trials":608,"activeCount":81},[],{"trials":610,"activeCount":81},[],{"trials":612,"activeCount":81},[],{"trials":614,"activeCount":81},[],{"intervention":616,"totalTrials":9,"cells":617},"Intravenous injection of [99mTc]Tc-DB8",{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":630,"PHASE3":632,"PHASE4":634,"NA":636},{"trials":619,"activeCount":81},[],{"trials":621,"activeCount":81},[622],{"nctId":623,"briefTitle":624,"status":242,"phases":625,"primaryCompletion":626,"completion":244,"start":627,"enrollment":548,"conditions":628,"interventions":629},"NCT05940298","Molecular Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8",[71],"2024-06-01","2023-07-03",[32,26],[616],{"trials":631,"activeCount":81},[],{"trials":633,"activeCount":81},[],{"trials":635,"activeCount":81},[],{"trials":637,"activeCount":81},[],{"intervention":639,"totalTrials":9,"cells":640},"One single intravenous injection of [177Lu]Lu-BQ7876",{"EARLY_PHASE1":641,"PHASE1":643,"PHASE2":656,"PHASE3":658,"PHASE4":660,"NA":662},{"trials":642,"activeCount":81},[],{"trials":644,"activeCount":81},[645],{"nctId":646,"briefTitle":647,"status":242,"phases":648,"primaryCompletion":649,"completion":650,"start":651,"enrollment":652,"conditions":653,"interventions":655},"NCT06641219","Clinical Evaluation of [177Lu]Lu-BQ7876 for Targeting of Prostate-Specific Membrane Antigen",[71],"2024-12-01","2025-02-28","2024-10-01",7,[654],"Prostate Cancers",[639],{"trials":657,"activeCount":81},[],{"trials":659,"activeCount":81},[],{"trials":661,"activeCount":81},[],{"trials":663,"activeCount":81},[],{"intervention":665,"totalTrials":9,"cells":666},"Diagnostic Test: whole body study and SPECT with [99mTc]Tc(CO)3-(HE)3-Ec1",{"EARLY_PHASE1":667,"PHASE1":669,"PHASE2":679,"PHASE3":681,"PHASE4":683,"NA":685},{"trials":668,"activeCount":81},[],{"trials":670,"activeCount":81},[671],{"nctId":672,"briefTitle":673,"status":242,"phases":674,"primaryCompletion":244,"completion":244,"start":675,"enrollment":548,"conditions":676,"interventions":678},"NCT05620472","Molecular Imaging of EpCAM Receptors Using [99mTc]Tc(CO)3-(HE)3-Ec1",[71],"2022-10-01",[677],"Solid Tumor, Adult",[665],{"trials":680,"activeCount":81},[],{"trials":682,"activeCount":81},[],{"trials":684,"activeCount":81},[],{"trials":686,"activeCount":81},[],{"intervention":688,"totalTrials":689,"cells":690},"99mTc-DARPinG3",2,{"EARLY_PHASE1":691,"PHASE1":693,"PHASE2":695,"PHASE3":697,"PHASE4":699,"NA":701},{"trials":692,"activeCount":81},[],{"trials":694,"activeCount":81},[],{"trials":696,"activeCount":81},[],{"trials":698,"activeCount":81},[],{"trials":700,"activeCount":81},[],{"trials":702,"activeCount":81},[703,711],{"nctId":704,"briefTitle":705,"status":242,"phases":706,"primaryCompletion":514,"completion":707,"start":515,"enrollment":215,"conditions":708,"interventions":709},"NCT05376644","Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3",[75],"2023-01-21",[18],[710,688],"99mTc-ADAPT6",{"nctId":712,"briefTitle":713,"status":242,"phases":714,"primaryCompletion":514,"completion":715,"start":515,"enrollment":215,"conditions":716,"interventions":718},"NCT05412459","99mTc-DARPinG3-based HER2 Expression Molecular Imaging in HER2-positive Breast Cancer During Chemo+Targeted Therapy",[],"2023-01-31",[717,518],"HER2-positive Breast Cancer",[688],{"intervention":272,"totalTrials":9,"cells":720},{"EARLY_PHASE1":721,"PHASE1":723,"PHASE2":725,"PHASE3":727,"PHASE4":729,"NA":731},{"trials":722,"activeCount":81},[],{"trials":724,"activeCount":81},[],{"trials":726,"activeCount":81},[],{"trials":728,"activeCount":81},[],{"trials":730,"activeCount":81},[],{"trials":732,"activeCount":81},[733],{"nctId":262,"briefTitle":263,"status":242,"phases":734,"primaryCompletion":265,"completion":266,"start":267,"enrollment":268,"conditions":735,"interventions":736},[75],[270],[231,272],{"intervention":738,"totalTrials":9,"cells":739},"Standard therapy",{"EARLY_PHASE1":740,"PHASE1":742,"PHASE2":744,"PHASE3":746,"PHASE4":748,"NA":750},{"trials":741,"activeCount":81},[],{"trials":743,"activeCount":81},[],{"trials":745,"activeCount":81},[],{"trials":747,"activeCount":81},[],{"trials":749,"activeCount":81},[],{"trials":751,"activeCount":81},[752],{"nctId":753,"briefTitle":754,"status":242,"phases":755,"primaryCompletion":715,"completion":756,"start":757,"enrollment":758,"conditions":759,"interventions":763},"NCT04573751","The EPIVER Randomized Controlled Trial",[75],"2024-01-31","2020-12-30",104,[760,761,762],"ST Elevation Myocardial Infarction","Percutaneous Coronary Intervention","No-Reflow Phenomenon",[738,764,765,766],"Epinephrine","Verapamil","Epinephrine + verapamil",{"intervention":764,"totalTrials":9,"cells":768},{"EARLY_PHASE1":769,"PHASE1":771,"PHASE2":773,"PHASE3":775,"PHASE4":777,"NA":779},{"trials":770,"activeCount":81},[],{"trials":772,"activeCount":81},[],{"trials":774,"activeCount":81},[],{"trials":776,"activeCount":81},[],{"trials":778,"activeCount":81},[],{"trials":780,"activeCount":81},[781],{"nctId":753,"briefTitle":754,"status":242,"phases":782,"primaryCompletion":715,"completion":756,"start":757,"enrollment":758,"conditions":783,"interventions":784},[75],[760,761,762],[738,764,765,766],{"intervention":765,"totalTrials":9,"cells":786},{"EARLY_PHASE1":787,"PHASE1":789,"PHASE2":791,"PHASE3":793,"PHASE4":795,"NA":797},{"trials":788,"activeCount":81},[],{"trials":790,"activeCount":81},[],{"trials":792,"activeCount":81},[],{"trials":794,"activeCount":81},[],{"trials":796,"activeCount":81},[],{"trials":798,"activeCount":81},[799],{"nctId":753,"briefTitle":754,"status":242,"phases":800,"primaryCompletion":715,"completion":756,"start":757,"enrollment":758,"conditions":801,"interventions":802},[75],[760,761,762],[738,764,765,766],{"intervention":766,"totalTrials":9,"cells":804},{"EARLY_PHASE1":805,"PHASE1":807,"PHASE2":809,"PHASE3":811,"PHASE4":813,"NA":815},{"trials":806,"activeCount":81},[],{"trials":808,"activeCount":81},[],{"trials":810,"activeCount":81},[],{"trials":812,"activeCount":81},[],{"trials":814,"activeCount":81},[],{"trials":816,"activeCount":81},[817],{"nctId":753,"briefTitle":754,"status":242,"phases":818,"primaryCompletion":715,"completion":756,"start":757,"enrollment":758,"conditions":819,"interventions":820},[75],[760,761,762],[738,764,765,766],{"intervention":710,"totalTrials":9,"cells":822},{"EARLY_PHASE1":823,"PHASE1":825,"PHASE2":827,"PHASE3":829,"PHASE4":831,"NA":833},{"trials":824,"activeCount":81},[],{"trials":826,"activeCount":81},[],{"trials":828,"activeCount":81},[],{"trials":830,"activeCount":81},[],{"trials":832,"activeCount":81},[],{"trials":834,"activeCount":81},[835],{"nctId":704,"briefTitle":705,"status":242,"phases":836,"primaryCompletion":514,"completion":707,"start":515,"enrollment":215,"conditions":837,"interventions":838},[75],[18],[710,688],{"intervention":840,"totalTrials":9,"cells":841},"SNP polymorphisms of the promoter regions pro - and anti-inflammatory cytokines and angiogenic growth factor",{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":843,"activeCount":81},[],{"trials":845,"activeCount":81},[],{"trials":847,"activeCount":81},[],{"trials":849,"activeCount":81},[],{"trials":851,"activeCount":81},[],{"trials":853,"activeCount":81},[854],{"nctId":855,"briefTitle":856,"status":242,"phases":857,"primaryCompletion":858,"completion":858,"start":859,"enrollment":298,"conditions":860,"interventions":861},"NCT04296253","Biomarkers and SNP-polymorphisms in Post-infarction Cardiac Remodeling",[],"2020-09-30","2019-03-15",[21],[840],{"intervention":863,"totalTrials":9,"cells":864},"[99mTc]Tc-G3-(G3S)3C",{"EARLY_PHASE1":865,"PHASE1":867,"PHASE2":869,"PHASE3":871,"PHASE4":873,"NA":875},{"trials":866,"activeCount":81},[],{"trials":868,"activeCount":81},[],{"trials":870,"activeCount":81},[],{"trials":872,"activeCount":81},[],{"trials":874,"activeCount":81},[],{"trials":876,"activeCount":81},[877],{"nctId":878,"briefTitle":879,"status":242,"phases":880,"primaryCompletion":881,"completion":881,"start":882,"enrollment":548,"conditions":883,"interventions":884},"NCT05923268","Molecular Imaging of HER2 Expression in Breast Cancer Using [99mTc]Tc-G3-(G3S)3C Before Chemo\u002FTargeted Therapy",[75],"2024-06-15","2023-06-04",[18],[863],{"intervention":886,"totalTrials":9,"cells":887},"Pharmaco-invasive strategy",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":889,"activeCount":81},[],{"trials":891,"activeCount":81},[],{"trials":893,"activeCount":81},[],{"trials":895,"activeCount":81},[],{"trials":897,"activeCount":81},[],{"trials":899,"activeCount":81},[900],{"nctId":901,"briefTitle":902,"status":242,"phases":903,"primaryCompletion":904,"completion":905,"start":906,"enrollment":472,"conditions":907,"interventions":911},"NCT03677466","Intramyocardial Haemorrhage in Patients With Primary STEMI",[75],"2018-10-30","2019-03-20","2018-01-25",[21,908,909,910],"STEMI","Myocardial Necrosis","Myocardial Injury",[886],{"intervention":284,"totalTrials":9,"cells":913},{"EARLY_PHASE1":914,"PHASE1":916,"PHASE2":918,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":915,"activeCount":81},[],{"trials":917,"activeCount":81},[],{"trials":919,"activeCount":81},[],{"trials":921,"activeCount":81},[],{"trials":923,"activeCount":81},[],{"trials":925,"activeCount":81},[926],{"nctId":274,"briefTitle":275,"status":242,"phases":927,"primaryCompletion":277,"completion":278,"start":279,"enrollment":280,"conditions":928,"interventions":929},[75],[282],[231,284],{"intervention":931,"totalTrials":9,"cells":932},"99mTc-DARPinG3 SPECT\u002FCT",{"EARLY_PHASE1":933,"PHASE1":935,"PHASE2":937,"PHASE3":939,"PHASE4":941,"NA":943},{"trials":934,"activeCount":81},[],{"trials":936,"activeCount":81},[],{"trials":938,"activeCount":81},[],{"trials":940,"activeCount":81},[],{"trials":942,"activeCount":81},[],{"trials":944,"activeCount":81},[945],{"nctId":946,"briefTitle":947,"status":242,"phases":948,"primaryCompletion":949,"completion":949,"start":950,"enrollment":951,"conditions":952,"interventions":953},"NCT05695859","99mTc-DARPinG3 SPECT\u002FCT for Non-invasive HER2-AX in Breast Cancer With Metastatic Lymph Nodes Before Targeted Therapy",[],"2023-12-01","2022-12-20",24,[18],[931],{"intervention":294,"totalTrials":9,"cells":955},{"EARLY_PHASE1":956,"PHASE1":958,"PHASE2":960,"PHASE3":962,"PHASE4":964,"NA":966},{"trials":957,"activeCount":81},[],{"trials":959,"activeCount":81},[],{"trials":961,"activeCount":81},[],{"trials":963,"activeCount":81},[],{"trials":965,"activeCount":81},[],{"trials":967,"activeCount":81},[968],{"nctId":286,"briefTitle":287,"status":242,"phases":969,"primaryCompletion":289,"completion":194,"start":290,"enrollment":291,"conditions":970,"interventions":971},[75],[282],[231,294]]